TMCnet News
Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual MeetingTORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from November 19-21, 2020. The presentations will include data and analyses from the MDNA55-05 trial, a recently completed Phase 2b trial evaluating MDNA55 in recurrent glioblastoma multiforme (rGBM) patients. Following completion of this trial and an End of Phase 2 Meeting, the United States Food and Drug Administration (FDA) has agreed that Medicenna can conduct an innovative open-label hybrid Phase 3 trial that allows for the use of a substantial number of subjects (two-thirds) from a matched external control arm to support regulatory approval of MDNA55 for rGBM. This trial design should provide the opportunity to accelerate the timelines and reduce the costs when compared with a traditional randomized control arm. Details of the on-demand oral presentations are below: Abstract ID: CTIM-13 The on-demand oral presentations will be available for viewing by conference attendees online here beginning on November 19, 2020 at 9:00 AM ET. Slides from the presentations will be posted to the “Events and Presentations” page of Medicenna’s website following the conference. About Medicenna Forward-Looking Statement The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law. Further Information For further information about the Company please contact: Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected] Investor Contact For more investor information, please contact: Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected] |